- NaviMed Capital, a Washington, DC area-based healthcare focused private equity firm, closed its second fund, NaviMed Partners II, at $290m
- NaviMed will continue to focus on control investments in fast growing lower middle-market healthcare services, healthcare IT, hospital products, and pharmaceutical services businesses
- The firm typically invests in profitable private companies with up to $10 million of EBITDA and double-digit annual revenue growth
- Since 2013, the firm has invested in 9 platform companies and completed more than 30 total acquisitions
- With the new fund, NaviMed now manages more than $400 of capital commitments
- The closing announcement follows the news last week of the announced sale of NaviMed portfolio company Velocity Clinical Research, a clinical trial services company
